Zydus Cadila starts supply of COVID-19 vaccine to govt

New Delhi: Drug firm Zydus Cadila on Wednesday said it has commenced supplies of its COVID-19 vaccine ZyCoV-D to the central government. The company has initiated the supply as per the order placed by the government, the drug firm said in a statement.

The group is also planning to make the vaccine available in the private market, it added.

ZyCoV-D is a three-dose vaccine administered intradermally.

“The vaccine will be priced at Rs 265 per dose and the applicator being offered at Rs 93 per dose, excluding GST,” Zydus Cadila said.

The Ahmedabad-based drugmaker has also entered into a definitive agreement with Shilpa Medicare Ltd, a contract manufacturing organisation, to produce mutually agreeable doses of ZyCoV-D.

It has also entered into an agreement with Enzychem Lifesciences of the Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine, Zydus Cadila noted.

ZyCoV-D is a Plasmid DNA vaccine that produces the spike protein of the SARS-CoV-2 virus and elicits an immune response mediated by the cellular and humoral arms of the human immune system, which play a vital role in protection from disease as well as viral clearance.

  • Related Posts

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Phase 2 results for LB-102 showed statistically significant reductions in PANSS total score across all doses with onset by week 1 and sustained through study end, alongside low rates of…

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    After substandard drug manufacturing, the state drug firms are once again under the scanner of the central government for manufacture and sale of unapproved fixed dose combination (FDC) drugs which…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    LB Pharma Begins Pivotal Phase 3 Schizophrenia Trial

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Check manufacturing, sale of 26 unapproved drugs, central regulator tells state authority

    Stem cell therapy for autism illegal: NMC advisory

    Stem cell therapy for autism illegal: NMC advisory

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    India’s Essential Medicines Prices To Increase Marginally From 1 April Under Annual Pricing Framework

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    Delhi HC Asks Dr Reddy’s To Halt Olymviq Sales; Flags Similarity With Novo Nordisk’s Ozempic

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise

    NPPA allows 0.64% hike in MRP of essential drugs in line with WPI rise